As clinically indicated, women should receive anti-osteoporosis drugs such as zoledronic acid, denosumab or oral bisphosphonates.

Aromatase inhibitors (AIs) are the first-line recommended standard of care for postmenopausal estrogen receptor-positive breast cancer.

Any breast cancer treatment - drugs or surgery - that reduces oestrogen levels in the body can increase the risk of osteoporosis and fractures.

These chemotherapies are commonly used in the management of breast cancer, and may promote ovarian dysfunction and accelerate bone loss in premenopausal women.

Adjuvant endocrine therapy induces bone loss and increases fracture risk in women with hormone-receptor positive, early-stage breast cancer (EBC).

13 сент. 2023 г. · Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group. Cancer Treat ...

Patients undergoing cancer treatment should be counseled on adequate calcium and vitamin D intake, and regular exercise including strength training. Assessment ...

Current literature recommends the use of bisphosphonates and denosumab in postmenopausal women with breast cancer treated with AIs.

29 февр. 2024 г. · It is recommended to choose endocrine drugs that have the least impact on bone safety to minimize the occurrence of bone safety problems. DRUG SAFETY MANAGEMENT · ACKNOWLEDGMENTS

16 авг. 2024 г. · Breast cancer treatments and menopause can both reduce bone density and lead to osteoporosis and osteopenia.